Fulvestrant stability with Super Refined excipients

The hormone therapy fulvestrant is indicated to treat oestrogen receptor positive (ER+), HER-2 negative metastatic breast cancer in post-menopausal women. Fulvestrant, delivered by intramuscular (IM) injection, works by blocking oestrogen from binding to cancer cells, and is known to result in a greater degree of progression-free survival than any other anti- oestrogen treatment in this specific patient subgroup.